Search | Page 6 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Clinical Utility of Lenalidomide in the Treatment of Myelodysplastic Syndromes

    ... Abstract:  Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes ... This article reviews lenalidomide in the setting of myelodysplastic syndromes (MDS). ...

    Research Review last updated 05/02/2016 - 9:12am.

  2. Recent developments in myelodysplastic syndromes

    ... approval of azacitidine , decitabine , and lenalidomide between 2004 and 2006 seemed to herald a new era in the ...

    Research Article last updated 04/29/2016 - 11:34am.

  3. Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS

    ... Received prior treatment for MDS with lenalidomide or hypomethylating agents (HMAs). History of one of the ...

    Clinical Trial last updated 06/19/2017 - 2:44pm.

  4. Myelodysplastic syndromes: Contemporary review and how we treat

    ... (HMA) azacitidine and decitabine and lenalidomide for MDS with isolated del(5q). To date, allogeneic stem ...

    Research Article last updated 04/29/2016 - 1:05pm.

  5. Personalized medicine for MDS

    ... treatment for MDS.  The classic example is the use of lenalidomide for patients with a del (5q) abnormality.  -In recent ... and the average length of response is 2 years.  -Lenalidomide works best in patients with red blood cell transfusion ...

    Research Review last updated 05/02/2016 - 9:44am.

  6. Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study

    ... isolated del(5q). METHODS: Patients received lenalidomide 10 mg/day (days 1-21; n = 47) or 5 mg/day (days 1-28; ... cycles, or placebo (n = 45). From the placebo and lenalidomide 5 mg groups, 84% and 58% of patients, respectively, crossed over ...

    Research Article last updated 07/29/2014 - 12:12pm.

  7. Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia

    ... Azacitidine Lenalidomide Phase:  Phase 2 ... is a restricted distribution program for receiving lenalidomide ) Females of childbearing potential (FCBP)† must have a ...

    Clinical Trial last updated 06/06/2016 - 1:30pm.

  8. Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents.

    ... supportive care alone, cytotoxic therapy, lenalidomide , histone deacetylase inhibitors, and HSCT, favorable ...

    Research Article last updated 11/19/2015 - 8:32am.

  9. Anemia as the Main Manifestation of Myelodysplastic Syndromes

    ... in hereditary anemias like Blackfan Diamond anemia. Lenalidomide is the agent that has shown striking and specific ...

    Research Article last updated 12/02/2015 - 8:45am.

  10. Incidence and Burden of the Myelodysplastic Syndromes

    ... despite strong evidence that hypomethylating agents and lenalidomide significantly reduce transfusion burden. Other unmet needs ...

    Research Article last updated 10/14/2015 - 8:44am.